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Background. Metaboreﬂex overactivation has been proprosed to explain exaggerated hyperventilation in heart failure population.
We investigated the metaboreﬂex activation after cardiac resynchronization therapy (CRT). Methods. 10 heart failure patients
(mean left ventricular ejection fraction (LVEF) 27±4%) schedulded for CRT implantation were prospectively studied. At baseline
and after 6 month follow up two maximal cardiopulmonary exercise tests with and without regional circulatory occlusion (RCO)
during recovery were performed. RCO was achieved by inﬂation of bilateral upper thigh tourniquets 30mmHg above peak systolic
blood pressure during 3 minutes after peak exercise. Metaboreﬂex contribution to the ventilatory response was assessed as the
diﬀerence in ventilatory data at the third minute during recovery between the two tests (Δ). Results. Patients had enhanced
VE/VCO2 slope (40 ± 9) and an evident metaboreﬂex contribution to the high ventilatory response (ΔVE: 3 ± 4L/min; P = 0.05,
ΔRR: 4.5±4/min; P = 0.003 and ΔVE/VCO2:5 .5±4; P = 0.007). 6 months after CRT implantation, NYHA class, LVEF, peak VO2
and VE/VCO2 were signiﬁcantly improved (1.4 ± 0.5; P<0.001, 42 ± 7%; P<0.001, 16.5 ± 3mL/kg/min; P = 0.003; 33 ± 10;
P = 0.01). Metaboreﬂex contribution to VE, RR, and VE/VCO2 was reduced compared with baseline (P = 0.08, P = 0.01 and
P = 0.4r e s p . ) .Conclusion. 6 months after CRT metaboreﬂex contribution to the ventilatory response is reduced.
1.Introduction
Patients suﬀering from chronic heart failure (HF) have con-
stant impaired exercise response with a reduced peak oxy-
gen consumption and an exaggerated ventilatory response
expressed by an increase in the slope relating the minute
ventilation (VE) to the carbon dioxide production (VCO2)
[1]. Nevertheless, pathophysiological basis of such as hyper-
ventilationremainunclear.Animportantcauseofhyperpnea
during eﬀort would be the enlargement of physiological
dead space and ventilation-perfusion mismatch by alveolar
hypoperfusion from hemodynamic dysfunction. Another
determinant is the early cardiorespiratory reﬂex dysreg-
ulation. This was evidenced by increased peripheral and
central chemosensitivity, impaired sympathovagal balance
with sympathetic predominance and depressed baroreﬂex
circulation control [2]. In addition, muscle metaboreﬂex
contribution to the ventilatory response has been extensively
investigated in heart failure. Of particular interest, Piepoli
et al. found a signiﬁcant overactivation of the peripheral
metaboreﬂex (group III and IV intramuscular aﬀerents
sensitive to metabolic products of skeletal muscle work)
leading to an early hyperventilation during exercise and a
highVE/VCO2 slopeinheartfailurepopulation[3].Piepoli’s
“muscle hypothesis” is explained by structural, metabolic,
and perfusion muscular changes. In particular, both
a reduction in capillar density and a shift from slow-twitch
type 1 muscular ﬁbres to fast-twitch type 2 ﬁbres were pre-
viously reported. It leads to depressed oxidative capacity and
maximal oxygen consumption by a signiﬁcant reduction of2 Cardiology Research and Practice
mitochondrial density and an increase of the glycogenolytic
metabolism with a high production of carbon dioxide
leading to early anaerobic threshold and high respiratory
exchange ratio (RER) at peak of the exercise [4, 5]. These
muscular changes and inadequate perfusion of exercising
muscles may cause local overproduction and accumulation
of muscle metabolic byproducts which trigger stimulation of
group III and IV neural aﬀerents (metaboreceptors) [6, 7].
In previous investigation authors found a signiﬁcant
improvement in exercise capacity after cardiac resynchro-
nization therapy (CRT). Of particular interest, we demon-
strated signiﬁcant improvement of maximal oxygen con-
sumption, reduction of the peak RER, and a later anaerobic
threshold assessing a signiﬁcant improvement in oxidative
capacity.Inaddition,ventilatoryresponsebyVE/VCO2 slope
is reduced after CRT. But it remains unclear how CRT could
improve the ventilatory response [8–10].
We aim to investigate exercise oxidative capacity, venti-
latory response, and metaboreﬂex activation before and 6
months after CRT implantation. We suggest that ventilatory
response improvement is associated with a signiﬁcant reduc-
tion of the metaboreﬂex activation.
2. Methods
Refractory HF patients matching the following criteria were
prospectively included in the study: indication for CRT
implantation according to current indications (QRS dura-
tion > 1 2 0m s ,L Ve j e c t i o nf r a c t i o n< 35%, NYHA symptom
class II/III or IV, and optimal heart failure medical regimen).
From 2 days before CRT implantation, patients underwent
clinical and echocardiographic evaluation. In addition, they
performed two maximal cardiopulmonary exercise testing
for an evaluation of the metaboreceptor contribution to
ventilatory response in the lower limb by a regional circu-
latory occlusion (RCO). After 6-month followup, patients
underwent similar clinical, echocardiographic and exercise
evaluation.
2.1. Clinical Evaluation. All patients scheduled for CRT and
included in this study underwent evaluation before and 6
months after CRT implantation including a clinical (NYHA
class, 6-minute hall-walk test, and a quality of life assessment
using Minnesota Living with Heart Failure test) and a 12-
lead electrocardiogram for heart rate and QRS duration
measurement.
2.2. Echocardiographic Measurement. 2D echocardiograms
were performed using a 5.0MHz imaging probe connecting
to an ultrasound system (Vivid 7, Vingmed-General Electric,
Horten, Norway). Echocardiograms were loaded into a
computer system (Echopac, GE), and all measurements were
obtained for all patients at baseline and 6 months after
implantation. Echocardiograms were analyzed by a single
experiencedsonographer.Sampleloopswereanalyzedoﬄine
on an Echopac computer workstation to obtain teledias-
tolic (TDV) and tele-systolic LV (TSV) volumes using the
methods of disks. Ejection fraction was calculated as follows:
(TDV −TSV)/TDV ×100%.
2.3.TestingProcedureandDataCollection. Symptom-limited
exercises test with ventilatory expired gas analysis were
performed using a cycle ergometer with a 10watts/minute
protocol (Ergocard, Medisoft, Sorinnes, Belgium). Continu-
ous standard 12-lead electrocardiograms, right arm manual
bloodpressuremeasurements,andheartraterecordingswere
monitored at every stage. Data for oxygen consumption
(VO2), carbon dioxide production (VCO2), minute ventila-
tion(VE),respiratoryrate(RR),andworkloadwerecollected
continuously throughout the exercise. Oxygen and carbon
dioxide sensors were calibrated using gases with known
oxygen, nitrogen, and carbon dioxide concentrations prior
to each test.
Ventilatory eﬃciency during exercise was obtained by
the linear regression slope relating VE to VCO2 from the
beginning to the peak of the eﬀort [11]. The peak circulatory
power was measured as the product of the peak VO2 and
the systolic blood pressure as described previously [12]. The
respiratoryexchangeratio(RER)atpeakwasmeasuredusing
the rapport between the VCO2 and the VO2. The anaerobic
threshold was assessed by the Wasserman’s method. During
passive recovery VE, RR, and VE/VCO2 were collected at 1,
2, and 3 minutes.
2.4.MetaboreceptorTest. Theevaluationofthemetaborecep-
tor contribution to ventilatory data (VE, RR and VE/VCO2)
in the lower limb included two exercises (24 hours interval):
(a) a maximal exercise test with gas exchange measurement
according to the precedent protocol followed by a passive
recovery and (b) a maximal exercise test at the same level
(duration and work load) followed by a venous and arterial
regional circulatory occlusion (RCO) by inﬂation of bilateral
upper thigh tourniquets to 30mmHg above peak exercise
arm systolic pressure. During both recoveries VE, RR, and
VE/VCO2 were collected at 1, 2 and 3 minutes. After 3
minutes RCO was released. The contribution of the muscle
metaboreceptors was evaluated by trapping the metabolites
in the exercising muscle after exercise. This protocol has
been shown to ﬁx the metabolic state of the muscle and to
maintain the activation of the metaboreﬂex [13, 14]. The
metaboreﬂex contribution to the ventilatory response was
deﬁned as the diﬀerence (Δ) in VE, RR, and VE/VCO2 at the
third minute recovery with and without RCO.
2.5. CRT Implantation. All patients received a biventricular
pacingdeviceforCRTwitharightventricularapicalleadand
left ventricular (LV) lead positioned through the coronary
sinus in an LV epicardial vein. Biventricular pacing program-
mation including atrioventricular delay was achieved by an
experienced physician for optimal hemodynamic results.
2.6. 6-Month Followup. A similar evaluation including clin-
ical, echocardiographic, and metaboreﬂex assessments was
performed.
2.7.StatisticalAnalysis. Variablesaresummarizedbymean±
SD. Paired t-tests were used to compare diﬀerences between
parameters at baseline and after CRT within our population.Cardiology Research and Practice 3
Table 1: Baseline characteristics. Values are given as means ±
S.E.M. BNP, brain natriuretic peptid; BP, blood pressure; EF,
ejection fraction; LV, left ventricle; QOL: quality of life; TDV, tele-





Weight (kg) 79 ±16
Systolic BP (mmHg) 114 ±16
Heart rate (/min) 69 ±11
NYHA status 2.4 ±0.5
Etiology
Ischemia n = 4
Idiopathic n = 5
Valvular n = 1
QRS (ms) 147 ±27
LV EF (%) 27 ±4
LV TSV (mL) 142 ±58
LV TDV (mL) 205 ±68
6-minute walking test (meters) 460 ±84
QOL score (Minnesota) 24 ±14
Creatinine (micromole/L) 93 ±13




All statistical tests with a P value of <0.05 were considered to
be signiﬁcant.
3. Results
3.1. Clinical and Echocardiographic Parameters at Baseline.
Ten patients (age: 62 ± 9 years) were included in this study.
Baseline characteristics are summarized in Table 1. Patients
had severe depressed left ventricular ejection fraction (LVEF:
27 ± 4%) and signiﬁcant LV dilation (LV tele-systolic
volume: 142 ± 58mL). Mean NYHA status and six-minute
walking test were increased at 2.4 ± 0.5 and 460 ± 84 meters
respectively with a mean quality of life score at 24±14. Mean
brain natriuretic peptide (BNP) was at 371 ± 182pg/mL.
Mean heart rate and QRS duration were at 69 ± 11/minute
and 147 ±27ms.
3.2. Exercise and Metaboreﬂex Test at Baseline. Patients had
a reduced peak of VO2 at 14 ± 4mL/kg/min with a high
ventilatory response (mean VE/VCO2 slope at 39 ± 10).
Mean peak workload and exercise duration were at 80 ±
25 watts and 474 ± 156 seconds. The mean peak circulatory
power was at 2320±821mL/kg/min·mmHg. The mean peak
RER and the mean time to anaerobic threshold were at
1.31 ± 0.18 and 163 ± 94 seconds. All subjects completed
the metaboreceptor protocol without complication. The
ventilatory variables increased similarly during the exercises
without and with postexercise RCO (P>0.05; Table 2).
During recovery, ventilation expressed as VE, RR, and
VE/VCO2 was higher at the third minute with RCO than
withoutRCO(ΔVE: 3±4 L/min;P = 0.05,ΔRR:4.5±3/min;
P = 0.003, ΔVE/VCO2:5 .5 ± 4; P = 0.007) (Table 3). These
results assessed the signiﬁcant metaboreﬂex contribution to
the ventilatory response before CRT.
3.3. Clinical and Echocardiographic Parameters after 6-Month
Followup. All patients were implanted with a CRT device
without complication and all subjects had a permanent
(>99% of the time) biventricular pacing during rest and at
peak of exercise. Patients experienced a signiﬁcant reduction
of dyspnea (mean NYHA status 1.4 ± 0.5, P = 0.0002)
without signiﬁcant changes of the 6-minute walking test and
the quality of life score (527 ± 214 meters, P = 0.28 and
21±15, P = 0.24, resp.). Mean QRS duration and BNP were
reduced to 129±31ms (P = 0.1) and 150±145pg/mL (P =
0.06). In our population we found a nonsigniﬁcant increase
of the mean consumption of betablocker and ACE inhibitors
(P = 0.11). In addition, mean LVEF and LV tele-systolic
volume were signiﬁcantly improved to 39 ± 9% (P = 0.006)
and 87 ±46mL (P = 0.04).
3.4. Exercise and Metaboreﬂex Test after 6-Month Followup
(Tables 3 and 4). Mean peak of VO2 was signiﬁcantly
improved at 16.5 ± 3mL/kg/min (P = 0.003) with
a nonsigniﬁcant postponed anaerobic threshold at 195 ±
69 seconds (P = 0.06). Mean peak RER was reduced to
1.2±0.1(P = 0.1).Theventilatoryresponsewassigniﬁcantly
improved (VE/VCO2 slope: 33 ± 10, P = 0.01) after CRT.
Nevertheless, mean exercise duration and maximal workload
were not signiﬁcantly increased (552±142 seconds; P = 0.15
and 93±23 watts). However, hemodynamic condition at the
peak of exercise was improved (peak systolic blood pressure:
168 ± 31mmHg; P = 0.0 1a n dp e a kc i r c u l a t o r yp o w e r :
2770 ± 791mL/kg/min·mmHg; P = 0.004). After 6-month
followup, the VE and the RR were lower at the third minute
of recovery with RCO than without RCO. But the VE/VCO2
was not signiﬁcantly increased anymore (ΔVE: −1±5L/min;
P = 0.6, ΔRR: −1 ± 3/min; P = 0.53, ΔVE/VCO2:
3.5 ± 4; P = 0.06). The negative eﬀect of circulatory
occlusionafter6-monthfollowupsuggeststhenonsigniﬁcant
metaboreﬂex contribution to the ventilatory response after
CRT. In addition, the metaboreﬂex contribution to RR was
signiﬁcantly reduced (P = 0.01) after CRT. Nevertheless,
the metaboreﬂex contribution to VE and VE/VCO2 was not
signiﬁcantly reduced (P = 0.08 and P = 0.4).
4. Discussion
This study provides, for the ﬁrst time, the evidence that CRT
may reduce the metaboreﬂex contribution to the ventilatory
response in a refractory heart failure population. We ﬁrst
demonstrate that such a device may have a peripheral eﬀect
with a signiﬁcant improvement of the ventilatory response.
This observation is of particular interest to understand
pathophysiological basis of the response after CRT. We
ﬁrst suggested such a hypothesis in previous trial with a4 Cardiology Research and Practice
Table 2: Comparison of ventilatory data during rest and peak exercise with and without RCO before and 6 months after CRT. Values are
given as means ± SEM. RCO, regional circulatory occlusion, RR, respiratory rate, VE, minute ventilation.
Before CRT After-6 month followup
Normal RCO Normal RCO
VE at rest (L/min) 12 ±31 3 ±41 2 ±31 3 ±2
Peak VE (L/min) 51 ±17 52 ±14 54 ±14 54 ±13
Peak VCO2 (L/min) 1.33 ±0.51 .4 ±0.41 .5 ±0.41 .5 ±0.4
RR at rest (/min) 16 ±51 8 ±31 8 ±31 6 ±3
Peak RR (/min) 30 ±53 0 ±53 2 ±53 1 ±4
Table 3: Comparison of exercise data before and after CRT. Values are given as means ± SEM. AT, anaerobic threshold; BP, blood pressure;
CP, circulatory power. ∗P<0.05 compared with baseline.
Before CRT After 6-month followup
Heart rate at rest (/min) 69 ±11 70 ±7
Peak heart rate (/min) 114 ±25 116 ±19
Peak systolic BP (mmHg) 150 ±30 168 ±31
∗
M a x i m a lw o r k l o a d( W a t t s ) 8 0±25 93 ± 23
Peak VO2 (mL/kg/min) 14 ±41 6 .5 ±3
∗
Time to AT (seconds) 163 ±94 195 ±69
VE at rest (L/min) 12 ±31 3 ±3
Peak VE (L/min) 51 ±17 54 ± 14
Peak VCO2/VO2 1.31 ±0.18 1.2 ± 0.1
VE/VCO2 slope 39 ±10 33 ±10
∗
Peak CP (mL/kg/min·mmHg) 2320 ±821 2770 ±791
∗
Duration of exercise (seconds) 474 ±156 552 ± 142
signiﬁcant reduction of the peak RER and a later anaerobic
threshold 6 months after CRT [8] .T h e s eo b s e r v a t i o n ss u g -
gested a postponed anaerobic muscular metabolism during
exercise. Indeed, it is well known that patients suﬀering from
chronic heart failure have muscular dysfunctions leading to
an early anaerobic metabolism with a high carbon dioxide
production, a reduction in maximal oxygen consumption
and reduced eﬀort capacities. Skeletal muscle blood ﬂow
is limited in HF population by low cardiac output and
increased peripheral resistance by sympathetic tone overac-
tivation and endothelial dysfunction [15, 16]. In addition,
there is also evidence for a reduced percentage of slow-twitch
type 1 ﬁbres with oxidative enzyme content and an increased
percentage of fast-twitch type 2 ﬁbres with high glycolytic
capacity [2]. Then, authors found signiﬁcant reduction in
oxidative enzyme activity, in mitochondrial density leading
to muscular metabolites accumulation (lactates, hydrogen,
prostaglandin, bradykinin etc.). These muscular changes
were well correlated with an overactivation of the meta-
boreﬂex leading to high ventilatory response in heart failure
[6, 7, 17].
In our investigation, we conﬁrmed a signiﬁcant improve-
ment in oxidative capacity after CRT with an increase
of the maximal oxygen consumption and a trend toward
postponed anaerobic threshold. Nevertheless, the peak RER
was not signiﬁcantly improved. In addition, our patients
experienced a signiﬁcant improvement in the ventilatory
response expressed as the linear regression slope of the
VE/VCO2.
In this study, we conﬁrmed the signiﬁcant metaboreﬂex
contribution to ventilatory parameters as VE (P = 0.05),
RR (P = 0.003) and VE/VCO2 (P = 0.007) in the
lower limb. Nevertheless, metaboreﬂex contribution to the
minute ventilation was lesser than in other trials [13].
This observation is in accordance with results reported
b yF r a n c i se ta l .[ 18]. Authors did not ﬁnd a signiﬁcant
metaboreﬂex contribution to the VE. These results were
against a signiﬁcant role of muscle metaboreceptors in the
genesis of the exercise hyperventilation of patients with
HF. However, in this study patients probably had a less
severe degree of heart failure than those in our and Scott’s
investigation (peak of VO2 of 22 ± 5mL/min/kg versus
14 ± 4mL/min/kg and 18 ± 2mL/min/kg, resp.) [13]. But
our ﬁndings do not contradict previous studies because of
diﬀerences of protocol. In addition, metaboreﬂex contribu-
tion to the respiratory rate and the VE/VCO2 ratio during
recovery appears clearly signiﬁcant. These observations are
in accordance with normal physiology. Unlike the minute
ventilation,itiswellknownthatRRincreasedduringtheend
of exercise in normal population by anaerobic trigger. Thus,
RR seems to be more regulated by muscular metabolism
during exercise and then is more inﬂuenced by metareceptor
trigger.
Secondly, these study provides the evidence for a sig-
niﬁcant reduction of the metaboreﬂex contribution to the
respiratory rate and a nonsigniﬁcant reduction of the meta-
boreﬂex contribution to minute ventilation and VE/VCO2.
These results conﬁrmed the involvement of the peripheralCardiology Research and Practice 5
Table 4: Ventilatory variables during recovery with (RCO) and without (normal) regional circulatory occlusion. Values are given as means
± SEM. †P = 0.05 compared with data without RCO. ∗P<0.05 compared with data without RCO. #P<0.05 compared with baseline.
Recovery Parameters Before CRT After 6-month followup
Normal RCO Delta Normal RCO Delta
1st minute
VE (l/min) 40 ±13 43 ±92 ±74 5 ±94 1 ±9 −4 ±7
RR (/min) 27 ±42 7 ±40 .7 ±32 6 ±32 7 ±50 .4 ±3
VE/VCO2 39 ±11 39 ±11 −0.2 ±43 3 ±33 4 ±40 .8 ±3
2nd minute
VE (l/min) 28 ±53 2 ±64 ±73 5 ±63 1 ±6 −4 ±6
RR (/min) 22 ±42 4 ±42 .5 ±22 4 ±42 3 ±4 −0.5 ±3
VE/VCO2 40 ±11 42 ±11 1 ±43 5 ±33 7 ±53 .5 ±5
3rd minute
VE (l/min) 23 ±42 6 ±5
† 3 ±4 27 ±42 6 ±4 −1 ±5
RR (/min) 19 ±32 3 ±3
∗ 4.5 ±3 22 ±42 1 ±3 −1 ±3
#
VE/VCO2 41 ±11 46 ±11
∗ 5.5 ±4 36 ±43 9 ±6 3.5 ±4
muscle in the improvement of functional status after CRT.
These observations are of particular interest for a better
understanding of the pathophysiology of the response after
implantation. Previously, Piepoli et al. found a signiﬁcant
reduction of the metaboreﬂex activation after a training
protocolinaheartfailurepopulation[3].Inaddition,Guazzi
et al. provided evidence for a signiﬁcant attenuation of the
metaboreﬂex contribution to ventilation after cardioversion
of atrial ﬁbrillation associated with an improvement in the
ventilatory response [19]. These investigations conﬁrmed
the central role of the peripheral muscular changes in the
overactivation of the metaboreﬂex and the increase of the
ventilatory response in heart failure leading to dyspnea and
breathlessnessduringexerciseandreductionofqualityoflife.
But how does the CRT improve the metaboreﬂex? It
was assessed that metaboreﬂex activation is well correlated
with the muscular perfusion [19]. Thus, CRT was conﬁrmed
to improve microcirculation [20]. In our study, we found
a signiﬁcant increase of the LV ejection fraction and the
peak circulatory power assessing a signiﬁcant improvement
of hemodynamic condition after CRT. We suggest that CRT
couldimproveperipheralbloodﬂowbybetterhemodynamic
conditions leading to an increase of exercise capacities. It
could lead to a shift from fast-twitch type 2 ﬁbres to slow-
twitchtype1ﬁbreswithanincreaseinoxidative metabolism,
in mitochondrial density, in oxygen consumption and in
reduction in carbon dioxide production resulting in a
postponed anaerobic threshold and in a reduction of the
metaboreﬂex activation as observed after an exercise training
protocol [3, 21]. According to these results and those from
Patwala et al. we could emphasize the particular interest of
a systematic training program for refractory heart failure
population to increase the functional status and quality of
life improvement after CRT [22].
Nevertheless,thisstudyislimitedbythesmallpopulation
included, as well as the lack of control group. In addition, we
found no signiﬁcant improvement of the quality of life test,
the 6-minute walking test, the duration of exercise and the
maximal workload in our population. These results could
be explained by the functional status of our patients: 60%
of them were in class II of the NYHA status. Our patients
probably had a less severe degree of heart failure than those
in previous studies explaining the non signiﬁcant reduction
of the metaboreﬂex contribution to the minute ventilation.
In addition, a large metaboreﬂex eﬀect to arm exercise
was conﬁrmed, while a smaller eﬀect has been observed
during limb exercise. Using limb exercise and RCO, venous
return may not have been completely blocked from the
exercising muscle of the limb and may have underestimated
the metaboreﬂex contribution to the ventilatory response.
But according to previous studies metaboreﬂex evaluation
using arm RCO was too painful for subjects to withstand for
3m i n u t e s[ 13].
5. Conclusion
We ﬁrst demonstrated the critical contribution of the meta-
boreﬂex reduction in the improvement of the ventilatory
response (VE/VCO2 linear regression slope) six months after
cardiac resynchronization. Whereas we found a signicant
reductionofthemetaboreﬂexcontributiontotherespiratory
rate, we only found a trend toward reduction of the meta-
boreﬂex contribution to the VE. However, this observation is
of particular interest to understand pathophysiological basis
of the functional response after CRT implantation. We sug-
gest that CRT could lead to a signiﬁcant increase of exercise
capacity and then to peripheral muscular remodelling with
a shift from anaerobic type 2 ﬁbres to high oxidative type 1
ﬁbres.Nevertheless,furtherstudyincludinghistologicdatais
needed to conﬁrm this study.
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